BRAF and melanoma: In order to provide the most clinically relevant assessment of the combination of an Aurora A kinase and MEK inhibitor in human tumor xenograft experiments, the MEK inhibitor trametinib, which is approved for clinical use in BRAF-mutated, advanced melanoma (Flaherty et al., 2012), was substituted for TAK-733.